TrialInternational journal of hematology2011

Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial.

Yuzuru Kanakura et al.PubMed ↗Publisher ↗

No numbers read from the abstract.